可生物降解的凝甲基烯基基微针:通过皮肤递送药物的新范式
Khazanah Nurain Nurdin1, Cecep Suhandi1, Ahmed Fouad Abdelwahab Mohammed2
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia.
Archives of pharmacal research
|May 7, 2025
概括
基于凝甲基烯 (GelMA) 的微针可以提供最少的侵入性通过皮肤递送药物. 在GelMA微针设计的创新显示出增强治疗应用的希望,克服当前的局限性.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 微针 (MNs) 是一种先进的透皮药物递送系统,以最小的侵入性,生物相容性和生物降解性而闻名.
- 基于凝甲基 (GelMA) 的MNs因其灵活性,机械强度和可调节性质而被突出,使其能够控制药物释放.
- 通过UV交联形成的GelMA水凝支持各种治疗用途,包括伤口愈合,癌症治疗和葡萄糖监测.
研究的目的:
- 审查基于GelMA的微针设计的最新进展.
- 探索基于GelMA的MNs作为有效的治疗设备的潜力.
- 确定基于GelMA的微针技术的挑战和未来方向.
主要方法:
- 对基于GelMA的微针制造和应用的当前文献的综述.
- 分析材料和设计创新,包括与纳米材料和天然聚合物的组合.
- 评估与皮肤透,药物负载和监管批准有关的挑战.
主要成果:
- 基于GelMA的MNs由于其可适应性特性,具有可控药物输送的显著潜力.
- 与纳米材料和天然聚合物的组合可以提高MN的效率并扩大其治疗范围.
- 在优化皮肤透,药物载荷能力和满足监管标准方面,仍然存在关键挑战.
结论:
- 基于GelMA的微针是先进的透皮药物输送的有希望的平台.
- 持续的材料和设计创新对于克服当前的局限性和实现GelMA MNs的全部治疗潜力至关重要.
- 需要进一步的研究和开发,以建立基于GelMA的MNs作为可靠的医疗器械.
相关概念视频
01:16Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...